Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo

Tenets of PTEN Tumor Suppression

Leonardo Salmena, Arkaitz Carracedo, Pier Paolo Pandolfi · Cell · 2008 · 1K citations · Full text

Medicine, Cancer Biology, Oncology +12

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 372 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

mTOR mediated anti-cancer drug discovery

Qingsong Liu, Carson C. Thoreen, Jinhua Wang et al. · Drug Discovery Today Therapeutic Strategies · 2009 · 174 citations · Full text

Medicine, Oncology, Pharmacology +12

A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation

Giovanna Bergamini, Kathryn M. Bell, Satoko Shimamura et al. · Nature Chemical Biology · 2012 · 146 citations

Life Sciences, Biochemistry, Immunology +12

(2<i>S</i>,3<i>S</i>)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-<i>N,N</i>-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-<i>a</i>]- pyridin-6-ylphenyl)butanamide:  A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Scott D. Edmondson, Anthony Mastracchio, Robert J. Mathvink et al. · Journal of Medicinal Chemistry · 2006 · 121 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16